Literature DB >> 24179894

Bromocriptine, a Dopamine (d2) Receptor Agonist, Used Alone and in Combination with Glipizide in Sub-Therapeutic Doses to Ameliorate Hyperglycaemia.

Harish Kumar V S1, Vinutha M B, Pradeep A N, Sathisha Aithal, Sindhura Reddy Baleed, Umakant N Patil.   

Abstract

INTRODUCTION: Bromocriptine, an ergot derivative, is an agonist at the dopamine 2 receptor and a sympatholytic. It is a well established drug in Parkinsonism, hyperprolactinaemia and acromegaly and it has various other clinical indications like induction of ovulation in female infertility. Bromocriptine has been evaluated in alloxan induced diabetic rats for its anti-hyperglycaemic effect with and without simultaneous use of glipizide.
METHODS: Diabetes was induced in albino rats by giving a single subcutaneous injection of alloxan in a dose of 150 mg/kg body weight. After 72 hours of giving alloxan injection, depending upon their blood glucose levels (350mg/dl and above), the rats were included into the study and they were divided into four groups, each comprising of 6 rats (n=24): Group 1 which was taken as control was given distilled water. Group 2 was treated with glipizide, a standard drug. Group 3 was treated with the test drug, bromocriptine and Group 4 was treated with sub therapeutic doses of test and standard drugs. The drugs were given to the diabetic rats once daily by oral route for 30 consecutive days, in order to assess their effects in terms of reduction in blood glucose levels. Blood glucose was estimated on 0(th), 10(th), 20(th), and 30(th) days of the study at fixed time intervals. RESULTS AND
CONCLUSION: Bromocriptine, which was used alone, lowered the blood glucose levels appreciably; whereas the concomitant administration of bromocriptine and glipizide in sub therapeutic doses produced a much more appreciable reduction. The results which were obtained in the group which received simultaneous administration of test and standard drugs in sub therapeutic doses were comparable to those of the group which received reference drug, glipizide. Hence, it can be concluded that bromocriptine may serve as a valuable adjunct to available anti-diabetic medication.

Entities:  

Keywords:  Alloxan; Anti-hyperglycaemic; Bromocriptine; Glipizide

Year:  2013        PMID: 24179894      PMCID: PMC3809633          DOI: 10.7860/JCDR/2013/5803.3347

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  12 in total

Review 1.  Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus.

Authors:  Jessica L Kerr; Erin M Timpe; Katherine A Petkewicz
Journal:  Ann Pharmacother       Date:  2010-10-26       Impact factor: 3.154

2.  Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects.

Authors:  A H Cincotta; A H Meier
Journal:  Diabetes Care       Date:  1996-06       Impact factor: 19.112

3.  Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women.

Authors:  Petra Kok; Ferdinand Roelfsema; Marijke Frölich; Johannes van Pelt; Marcel P M Stokkel; A Edo Meinders; Hanno Pijl
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-06-27       Impact factor: 4.310

4.  Effects of chronic bromocriptine (CB-154) treatment on the plasma glucose and insulin secretion response to neurocytoglucopenia in rats.

Authors:  A Ribeiro-de-Oliveira; R M Guerra; R B Fóscolo; U Marubayashi; A M Reis; C C Coimbra
Journal:  J Endocrinol       Date:  1999-08       Impact factor: 4.286

5.  Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.

Authors:  J Michael Gaziano; Anthony H Cincotta; Christopher M O'Connor; Michael Ezrokhi; Dean Rutty; Z J Ma; Richard E Scranton
Journal:  Diabetes Care       Date:  2010-03-23       Impact factor: 17.152

6.  Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes.

Authors:  Rajiv Mahajan
Journal:  Indian J Pharmacol       Date:  2009-08       Impact factor: 1.200

7.  Successful treatment with bromocriptine of hypertension associated with polycystic ovarian disease.

Authors:  M Ito; K Matsuura; A Aiko; K Matsui; T Yoshimura; H Okamura
Journal:  Acta Obstet Gynecol Scand       Date:  1987       Impact factor: 3.636

8.  Bromocriptine for induction of ovulation in normoprolactinaemic post-pill anovulation.

Authors:  H J van der Steeg; H J Bennink
Journal:  Lancet       Date:  1977-03-05       Impact factor: 79.321

9.  Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes.

Authors:  Richard Scranton; Anthony Cincotta
Journal:  Expert Opin Pharmacother       Date:  2010-02       Impact factor: 3.889

Review 10.  Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.

Authors:  Ralph A Defronzo
Journal:  Diabetes Care       Date:  2011-04       Impact factor: 19.112

View more
  3 in total

1.  Reduced insulin sensitivity is related to less endogenous dopamine at D2/3 receptors in the ventral striatum of healthy nonobese humans.

Authors:  Fernando Caravaggio; Carol Borlido; Margaret Hahn; Zhe Feng; Gagan Fervaha; Philip Gerretsen; Shinichiro Nakajima; Eric Plitman; Jun Ku Chung; Yusuke Iwata; Alan Wilson; Gary Remington; Ariel Graff-Guerrero
Journal:  Int J Neuropsychopharmacol       Date:  2015-02-25       Impact factor: 5.176

Review 2.  Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases.

Authors:  Alexander O Shpakov; Kira V Derkach; Lev M Berstein
Journal:  Future Sci OA       Date:  2015-11-01

Review 3.  Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-I.

Authors:  Raquel Vieira; Selma B Souto; Elena Sánchez-López; Ana López Machado; Patricia Severino; Sajan Jose; Antonello Santini; Ana Fortuna; Maria Luisa García; Amelia M Silva; Eliana B Souto
Journal:  Pharmaceuticals (Basel)       Date:  2019-10-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.